MX2017005156A - Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. - Google Patents
Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida.Info
- Publication number
- MX2017005156A MX2017005156A MX2017005156A MX2017005156A MX2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A MX 2017005156 A MX2017005156 A MX 2017005156A
- Authority
- MX
- Mexico
- Prior art keywords
- drug antibody
- determination
- effector function
- humanized
- drug
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con un inmunoensayo de anticuerpo de anti-fármaco para la determinación de la presencia de un anticuerpo anti-fármaco contra un anticuerpo de fármaco humano o humanizado de supresión de la función efectora, en una muestra que comprende la incubación de una muestra que comprende suero de sangre de mamífero con el receptor Fcgamma I humano de longitud completa o un fragmento de unión de región Fc del mismo, de modo que se forma un complejo entre el anticuerpo de anti-fármaco contra el anticuerpo de fármaco humano o humanizado de supresión de la función efectora presente en la muestra y el receptor Fcgamma I humano o el fragmento de unión de la región Fc del mismo, por lo que el receptor Fcgamma I humano de longitud completa o el fragmento de unión de la región Fc del mismo se conjuga a una etiqueta detectable, y la determinación del complejo formado por la etiqueta detectable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14191806 | 2014-11-05 | ||
PCT/EP2015/074495 WO2016071119A1 (en) | 2014-11-05 | 2015-10-22 | Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005156A true MX2017005156A (es) | 2017-08-08 |
Family
ID=52023155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005156A MX2017005156A (es) | 2014-11-05 | 2015-10-22 | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. |
Country Status (10)
Country | Link |
---|---|
US (1) | US11340234B2 (es) |
EP (2) | EP3736575A1 (es) |
JP (2) | JP6739428B2 (es) |
KR (1) | KR20170080590A (es) |
CN (1) | CN107076761B (es) |
BR (1) | BR112017004810A2 (es) |
CA (1) | CA2960453A1 (es) |
MX (1) | MX2017005156A (es) |
RU (1) | RU2719642C2 (es) |
WO (1) | WO2016071119A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101047207B1 (ko) * | 2006-03-09 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | 항-약물 항체 분석 |
EP3805757A4 (en) * | 2018-06-04 | 2022-03-23 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR DETECTING A COMPLEX |
TWI838388B (zh) | 2018-07-10 | 2024-04-11 | 美商雷傑納榮製藥公司 | 修飾結合分子以最小化已存在的交互作用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219730A (en) | 1982-09-28 | 1993-06-15 | New York University | Idiotype-anti-idiotype immunoassay |
US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
EP0170302A1 (fr) | 1984-06-27 | 1986-02-05 | l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire | Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques |
EP0243471A4 (en) | 1985-10-22 | 1989-07-11 | Cooper Lipotech Inc | SOLID PHASE LIPOSOME IMMUNOANALYSIS SYSTEM. |
JPH07509128A (ja) | 1992-07-13 | 1995-10-12 | バイオネブラスカ・インコーポレーテッド | 組換型ポリペプチドの修飾方法 |
US6753189B1 (en) | 1998-06-04 | 2004-06-22 | Mizuho Medy Co., Ltd. | Detection apparatus and method for the same |
EP1917854A1 (en) | 2006-11-06 | 2008-05-07 | F. Hoffmann-La Roche Ag | Method for producing anti idiotypic antibodies |
CN101896820A (zh) * | 2007-12-15 | 2010-11-24 | 霍夫曼-拉罗奇有限公司 | 区分测定 |
EP2277044B1 (en) * | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
US20110263762A1 (en) | 2008-11-05 | 2011-10-27 | Teijin Limited | Polylactic acid composition and molded article thereof |
RU2585488C2 (ru) * | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Способы и композиция для секреции гетерологичных полипептидов |
EP2354792A1 (en) * | 2010-02-08 | 2011-08-10 | Biomonitor A/S | Method for detecting anti-drug antibodies |
CA2795549A1 (en) * | 2010-04-29 | 2011-11-03 | Theradiag Sa | Methods for detecting antibodies |
MX343327B (es) * | 2011-02-17 | 2016-11-01 | Nestec Sa | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. |
EP2492689B8 (en) * | 2011-02-22 | 2013-12-25 | Bernhard-Nocht-Institut für Tropenmedizin | Detection of antibodies using an improved immune complex (IC) ELISA |
CN103476795B (zh) * | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | 抗体Fc变体 |
JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
-
2015
- 2015-10-22 WO PCT/EP2015/074495 patent/WO2016071119A1/en active Application Filing
- 2015-10-22 EP EP20169162.3A patent/EP3736575A1/en active Pending
- 2015-10-22 EP EP15784662.7A patent/EP3215853B1/en active Active
- 2015-10-22 MX MX2017005156A patent/MX2017005156A/es unknown
- 2015-10-22 RU RU2017117273A patent/RU2719642C2/ru active
- 2015-10-22 CA CA2960453A patent/CA2960453A1/en not_active Abandoned
- 2015-10-22 KR KR1020177011941A patent/KR20170080590A/ko not_active Application Discontinuation
- 2015-10-22 JP JP2017522804A patent/JP6739428B2/ja active Active
- 2015-10-22 CN CN201580056954.7A patent/CN107076761B/zh active Active
- 2015-10-22 BR BR112017004810A patent/BR112017004810A2/pt not_active IP Right Cessation
-
2017
- 2017-05-05 US US15/587,730 patent/US11340234B2/en active Active
-
2020
- 2020-06-09 JP JP2020099770A patent/JP2020170001A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016071119A1 (en) | 2016-05-12 |
JP2017532570A (ja) | 2017-11-02 |
RU2017117273A (ru) | 2018-12-06 |
EP3215853A1 (en) | 2017-09-13 |
CN107076761A (zh) | 2017-08-18 |
KR20170080590A (ko) | 2017-07-10 |
EP3215853B1 (en) | 2022-11-16 |
JP2020170001A (ja) | 2020-10-15 |
US20170343560A1 (en) | 2017-11-30 |
JP6739428B2 (ja) | 2020-08-12 |
US11340234B2 (en) | 2022-05-24 |
CA2960453A1 (en) | 2016-05-12 |
RU2017117273A3 (es) | 2019-05-14 |
BR112017004810A2 (pt) | 2017-12-12 |
RU2719642C2 (ru) | 2020-04-21 |
CN107076761B (zh) | 2020-05-05 |
EP3736575A1 (en) | 2020-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009021A (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco. | |
AU2018200278B2 (en) | Antibodies to aripiprazole and use thereof | |
MX2015012823A (es) | Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo. | |
EP3933406A3 (en) | Antibodies to risperidone and use thereof | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
MX2015015061A (es) | Anticuerpos modificados de union a receptor de fc neonatal (fcrn) humano y metodos de utilizacion. | |
PE20140612A1 (es) | Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple | |
MX2015016389A (es) | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. | |
MX2020004921A (es) | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo. | |
BR112015022844A2 (pt) | métodos para detecção de anticorpos para doadores específicos e sistemas para pratica destes | |
WO2014031668A3 (en) | Antibodies to quetiapine and use thereof | |
AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
MX2017011489A (es) | Detección de moléculas pequeñas mediante nanoporos a través de ensayos de competición. | |
EA202190237A1 (ru) | Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada) | |
MX2017005156A (es) | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. | |
RU2015104737A (ru) | Способ обнаружения мультиспецифического связывающего агента | |
EP3467498A4 (en) | MONOCLONAL ANTI-HUMAN HEMOGLOBIN ANTIBODY OR ANTIBODY KIT, INSOLUBLE CARRIER PARTICLE TO WHICH THE MONOCLONAL ANTI-HUMAN HEMOGLOBIN ANTIBODY IS IMMOBILIZED, AND MEASURING REAGENT AND MEASURING METHODS USED THEREOF | |
MX2017007209A (es) | Prueba y metodo para determinar anticuerpos de produccion de citotoxicidad dependiente del complemento (cdc). | |
EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
BR112022005404A2 (pt) | Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap) | |
BR112018017336A2 (pt) | método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão | |
RU2012127077A (ru) | Методика проведения иммунохроматографического анализа для серодиагностики | |
MY194325A (en) | Test object detection method, and immunoassay instrument and monoclonal antibody for same | |
RU2012154230A (ru) | Способ количественного определения d-антигена полиовирусов 1-3 типов | |
SG10201809158TA (en) | Device and method for detecting blood group antigens by means of an incomplete antibody |